Icon
+91 94997 68112
Login Register

INFUGEM - (1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML)

GEMCITABINE HYDROCHLORIDE None
1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML
Less Than $1000 mn
None None
None None
None None
INFUGEM is a nucleoside metabolic inhibitor indicated:  in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.  in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.  in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3)  as a single agent for the treatment of pancreatic cancer.
Yes
INFUGEM Patent 1
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.